research use only

Bisantrene (CS1) FTO inhibitor

Name: Bisantrene (CS1)
Brand: Selleck Chemicals
SKU: S9946
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S9946

Bisantrene (CS1, NSC-337766, CL 216,942) is an anthracene derivative with anti-tumor activity and a potent and selective FTO inhibitor.

Bisantrene (CS1) FTO inhibitor Chemical Structure

Quality Control

Batch: S994601 0.1MHCl]15 mg/mL]true]DMSO]3 mg/mL]true]Water]Insoluble]false Purity: 99.4%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.4

Related Targets	PRMT EZH2 MAT2A DNA Methyltransferase LSD1 JMJD G9a/GLP MLL NSD SETD
Other FTO Inhibitors	FB23-2 Dac51 TFA FB23 Rheic Acid

Solubility

In vitro
Batch:

0.1MHCl : 15 mg/mL

DMSO : 3 mg/mL (7.52 mM) Warmed with 60°C water bath; Ultrasonicated;
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	5%1MHCL 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.19mg/ml (0.48mM)	Taking the 1 mL working solution as an example, add 50 μL of 3.8 mg/ml clarified 1MHCL stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5%1MHCL 1 95 %Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.027mg/ml (0.07mM)	Taking the 1 mL working solution as an example, add 50 μL of 0.54 mg/ml clear 1MHCL stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	398.46	Formula	C₂₂H₂₂N₈	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	78186-34-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	FTO
References	[1] https://pubmed.ncbi.nlm.nih.gov/34727689/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-09)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06185751	RECRUITING	Multiple Myeloma	Washington University School of Medicine	2024-08-22	PHASE1
NCT07761572	NOT_YET_RECRUITING	Pulmonary Arterial Hypertension	Cereno Scientific AB	2026-09-15	PHASE2
NCT05950113	WITHDRAWN	Recurrent Multiple Myeloma; Refractory Multiple Myeloma	Jonsson Comprehensive Cancer Center	2024-03-28	PHASE1
NCT03710421	SUSPENDED	Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma	City of Hope Medical Center	2019-04-23	PHASE1
NCT06574958	UNKNOWN	ORR,OS,PFS	The Second Hospital of Shandong University	2024-04-30	EARLY_PHASE1
NCT04989335	UNKNOWN	Myelogenous Leukemia, Acute	Sheba Medical Center	2021-08-02	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):